
Ta Hsung Tung
Examiner (ID: 4022)
| Most Active Art Unit | 1102 |
| Art Unit(s) | 1744, 1104, 1753, 1106, 1102, 1743, 2899, 2701, 2901 |
| Total Applications | 1660 |
| Issued Applications | 1317 |
| Pending Applications | 54 |
| Abandoned Applications | 289 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 13944719
[patent_doc_number] => 10208115
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-02-19
[patent_title] => Amino acid sequences that modulate the interaction between cells of the immune system
[patent_app_type] => utility
[patent_app_number] => 15/050740
[patent_app_country] => US
[patent_app_date] => 2016-02-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 42
[patent_figures_cnt] => 42
[patent_no_of_words] => 148007
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15050740
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/050740 | Amino acid sequences that modulate the interaction between cells of the immune system | Feb 22, 2016 | Issued |
Array
(
[id] => 15468621
[patent_doc_number] => 10550173
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-02-04
[patent_title] => PVRIG polypeptides and methods of treatment
[patent_app_type] => utility
[patent_app_number] => 15/048975
[patent_app_country] => US
[patent_app_date] => 2016-02-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 223
[patent_figures_cnt] => 335
[patent_no_of_words] => 58535
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 281
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15048975
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/048975 | PVRIG polypeptides and methods of treatment | Feb 18, 2016 | Issued |
Array
(
[id] => 10812158
[patent_doc_number] => 20160158318
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-06-09
[patent_title] => 'METHODS FOR TREATING SCLERODERMA BY ADMINISTERING A SOLUBLE CTLA4 MOLECULE'
[patent_app_type] => utility
[patent_app_number] => 15/047849
[patent_app_country] => US
[patent_app_date] => 2016-02-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 102
[patent_figures_cnt] => 102
[patent_no_of_words] => 49017
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15047849
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/047849 | Methods for treating dermatomyositis or polymyositis by administering a soluble CTLA4 molecule | Feb 18, 2016 | Issued |
Array
(
[id] => 11419896
[patent_doc_number] => 20170028040
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-02-02
[patent_title] => 'METHOD FOR ENHANCING IMMUNE RESPONSE IN THE TREATMENT OF INFECTIOUS AND MALIGNANT DISEASES'
[patent_app_type] => utility
[patent_app_number] => 15/044613
[patent_app_country] => US
[patent_app_date] => 2016-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 35
[patent_figures_cnt] => 35
[patent_no_of_words] => 7972
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15044613
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/044613 | Method for enhancing immune response in the treatment of infectious and malignant diseases | Feb 15, 2016 | Issued |
Array
(
[id] => 11040198
[patent_doc_number] => 20160237154
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-08-18
[patent_title] => 'ANTIBODY THERAPEUTICS THAT BIND CTLA4'
[patent_app_type] => utility
[patent_app_number] => 15/043157
[patent_app_country] => US
[patent_app_date] => 2016-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 26545
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15043157
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/043157 | Antibody therapeutics that bind CTLA4 | Feb 11, 2016 | Issued |
Array
(
[id] => 11866191
[patent_doc_number] => 20170233476
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-08-17
[patent_title] => 'Antibody Therapeutics That Bind CTLA4'
[patent_app_type] => utility
[patent_app_number] => 15/043269
[patent_app_country] => US
[patent_app_date] => 2016-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 26548
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15043269
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/043269 | Antibody Therapeutics That Bind CTLA4 | Feb 11, 2016 | Abandoned |
Array
(
[id] => 11053360
[patent_doc_number] => 20160250322
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-09-01
[patent_title] => 'VECTOR CO-EXPRESSING VACCINE AND COSTIMULATORY MOLECULES'
[patent_app_type] => utility
[patent_app_number] => 15/016375
[patent_app_country] => US
[patent_app_date] => 2016-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 30
[patent_figures_cnt] => 30
[patent_no_of_words] => 26871
[patent_no_of_claims] => 42
[patent_no_of_ind_claims] => 10
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15016375
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/016375 | Vector co-expressing vaccine and costimulatory molecules | Feb 4, 2016 | Issued |
Array
(
[id] => 11025164
[patent_doc_number] => 20160222119
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-08-04
[patent_title] => 'ISOLATED B7-H4 SPECIFIC COMPOSITIONS AND METHODS OF USE THEREOF'
[patent_app_type] => utility
[patent_app_number] => 15/009082
[patent_app_country] => US
[patent_app_date] => 2016-01-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 33
[patent_figures_cnt] => 33
[patent_no_of_words] => 34153
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15009082
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/009082 | Isolated B7-H4 specific compositions and methods of use thereof | Jan 27, 2016 | Issued |
Array
(
[id] => 11018106
[patent_doc_number] => 20160215059
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-07-28
[patent_title] => 'ICOS BINDING PROTEINS'
[patent_app_type] => utility
[patent_app_number] => 15/006560
[patent_app_country] => US
[patent_app_date] => 2016-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 25
[patent_no_of_words] => 51483
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15006560
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/006560 | ICOS binding proteins | Jan 25, 2016 | Issued |
Array
(
[id] => 11784024
[patent_doc_number] => 09393301
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2016-07-19
[patent_title] => 'Immunopotentiative composition'
[patent_app_type] => utility
[patent_app_number] => 15/000863
[patent_app_country] => US
[patent_app_date] => 2016-01-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 32
[patent_no_of_words] => 14068
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15000863
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/000863 | Immunopotentiative composition | Jan 18, 2016 | Issued |
Array
(
[id] => 11210945
[patent_doc_number] => 09439962
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2016-09-13
[patent_title] => 'Immunopotentiative composition'
[patent_app_type] => utility
[patent_app_number] => 15/000869
[patent_app_country] => US
[patent_app_date] => 2016-01-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 32
[patent_no_of_words] => 14075
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15000869
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/000869 | Immunopotentiative composition | Jan 18, 2016 | Issued |
Array
(
[id] => 10799188
[patent_doc_number] => 20160145345
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-05-26
[patent_title] => 'Human Anti-B7RP1 Neutralizing Antibodies'
[patent_app_type] => utility
[patent_app_number] => 14/995983
[patent_app_country] => US
[patent_app_date] => 2016-01-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 25934
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14995983
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/995983 | Human anti-B7RP1 neutralizing antibodies | Jan 13, 2016 | Issued |
Array
(
[id] => 14145477
[patent_doc_number] => 10253097
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-04-09
[patent_title] => Isolated antibody
[patent_app_type] => utility
[patent_app_number] => 14/988938
[patent_app_country] => US
[patent_app_date] => 2016-01-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 43
[patent_no_of_words] => 22761
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 160
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14988938
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/988938 | Isolated antibody | Jan 5, 2016 | Issued |
Array
(
[id] => 11054475
[patent_doc_number] => 20160251436
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-09-01
[patent_title] => 'Anti-PD-1 Antibodies'
[patent_app_type] => utility
[patent_app_number] => 14/975769
[patent_app_country] => US
[patent_app_date] => 2015-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 27
[patent_no_of_words] => 20117
[patent_no_of_claims] => 46
[patent_no_of_ind_claims] => 20
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14975769
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/975769 | Anti-PD-1 antibodies | Dec 18, 2015 | Issued |
Array
(
[id] => 12118836
[patent_doc_number] => 20180002422
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-01-04
[patent_title] => 'METHODS FOR UPREGULATING IMMUNE RESPONSES USING COMBINATIONS OF ANTI-RGMb AND ANTI-PD-1 AGENTS'
[patent_app_type] => utility
[patent_app_number] => 15/533532
[patent_app_country] => US
[patent_app_date] => 2015-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 52969
[patent_no_of_claims] => 38
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15533532
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/533532 | Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents | Dec 6, 2015 | Issued |
Array
(
[id] => 10813767
[patent_doc_number] => 20160159927
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-06-09
[patent_title] => 'IDENTIFICATION OF VSIG8 AS THE PUTATIVE VISTA RECEPTOR (V-R) AND USE THEREOF TO PRODUCE VISTA/VSIG8 AGONISTS AND ANTAGONISTS'
[patent_app_type] => utility
[patent_app_number] => 14/960973
[patent_app_country] => US
[patent_app_date] => 2015-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 24
[patent_no_of_words] => 95182
[patent_no_of_claims] => 51
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14960973
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/960973 | Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists | Dec 6, 2015 | Issued |
Array
(
[id] => 10813745
[patent_doc_number] => 20160159905
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-06-09
[patent_title] => 'ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF'
[patent_app_type] => utility
[patent_app_number] => 14/958053
[patent_app_country] => US
[patent_app_date] => 2015-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 55062
[patent_no_of_claims] => 46
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14958053
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/958053 | Anti-PD-1 antibodies and methods of use thereof | Dec 2, 2015 | Issued |
Array
(
[id] => 11785020
[patent_doc_number] => 09394365
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2016-07-19
[patent_title] => 'Reducing systemic regulatory T cell levels or activity for treatment of alzheimer\'s disease'
[patent_app_type] => utility
[patent_app_number] => 14/957065
[patent_app_country] => US
[patent_app_date] => 2015-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 56
[patent_no_of_words] => 21366
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 117
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14957065
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/957065 | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease | Dec 1, 2015 | Issued |
| 14/955843 | Antibodies, Uses & Methods | Nov 30, 2015 | Abandoned |
Array
(
[id] => 13106899
[patent_doc_number] => 10072082
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-09-11
[patent_title] => Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
[patent_app_type] => utility
[patent_app_number] => 14/950748
[patent_app_country] => US
[patent_app_date] => 2015-11-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 24
[patent_no_of_words] => 39748
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 222
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14950748
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/950748 | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling | Nov 23, 2015 | Issued |